In a world no one forecast, own a business that outlives presidential social posts: 6 large-cap stocks with upside potential of up to 29%

For quite some time now, it has become increasingly hard to make sense of what is happening in the world. The old ...
MarketScreener

Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks 1,2 UME is the leading cause of ...
MarketScreener

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart compared ...

[For All Managers: Practical Tools for the Field #19] Even as AI Evolves, Have You Updated Your Role? The AI-Era 'Role Update' Diagnostic | 9 Checksheets to Inspect …

AI predicts 'when something will break.'Eventually, it will even suggest 'how to deal with it,' and further, it will begin to ...